Literature DB >> 8764358

Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitor.

J H Fleisch1, C T Armstrong, C R Roman, E D Mihelich, S M Spaethe, W T Jackson, J L Bobbitt, S Draheim, N J Bach, R D Dillard, M Martinelli, R Fouts, D W Snyder.   

Abstract

The primary objective of this study was to develop a functional assay that could provide rapid and reliable information on some pharmacologic characteristics of a novel inhibitor of human secretory phospholipase A2 (sPLA2). Guinea pig bronchoalveolar lavage (BAL) fluid, containing predominantly macrophages, eosinophils and epithelial cells, released thromboxane A2, as measured by thromboxane B2, in a concentration-dependent manner on exposure to recombinant human sPLA2 (rh-sPLA2). Similarly, n-formyl-L-methionyl-L-leucyl-L-phenylalanine (n-F-Met-Leu-Phe) or arachidonic acid also released this lipid mediator. Indomethacin, a cyclooxygenase inhibitor, blocked synthesis of thromboxane in response to these agents. p-Bromophenacylbromide-inactivated rh-sPLA2 was substantially less effective than the untreated enzyme in causing release of thromboxane. LY311727 is a potent indole-derived inhibitor of the isolated enzyme (IC50 = 23 nM). Incubation of this agent with BAL cells, just before addition of rh-sPLA2, reduced release of thromboxane with an IC50 = 1.8 x 10(-6) M. Specificity for sPLA2 was demonstrated in that LY311727, unlike indomethacin, did not reduce synthesis and subsequent release of thromboxane A2 in response to arachidonic acid. Using this technique as a basis, we determined whether LY311727 could sufficiently accumulate in lung after i.v. administration to inhibit rh-sPLA2-induced thromboxane A2 release from BAL cells. The compound, given i.v. to guinea pigs 5 min before collecting BAL fluid, produced a dose-dependent inhibition of rh-sPLA2 with an ED50 = 50 mg/kg. Thus, new in vitro and ex vivo assays were developed that permit functional evaluation of novel sPLA2 inhibitors. These techniques should serve as secondary assays for evaluation of human sPLA2 inhibitory activity from a chemical series and in addition provide initial data related to metabolic stability and distribution to the lung.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764358

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Aerosol delivery of muramyl dipeptide to rodent lungs.

Authors:  R J Pettis; I Hall; D Costa; A J Hickey
Journal:  AAPS PharmSci       Date:  2000

2.  Mechanical induction of group V phospholipase A(2) causes lung inflammation and acute lung injury.

Authors:  Angelo Y Meliton; Nilda M Muñoz; Lucille N Meliton; Anna A Birukova; Alan R Leff; Konstantin G Birukov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-22       Impact factor: 5.464

3.  Nitric oxide limits the eicosanoid-dependent bronchoconstriction and hypotension induced by endothelin-1 in the guinea-pig.

Authors:  K Lewis; A Cadieux; G A Rae; J P Gratton; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 4.  Biology of secretory phospholipase A2.

Authors:  Boris B Boyanovsky; Nancy R Webb
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-14       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.